Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Verastem (VSTM) EBT (2018 - 2025)

Verastem has reported EBT over the past 8 years, most recently at -$41.1 million for Q4 2025.

  • Quarterly results put EBT at -$41.1 million for Q4 2025, down 29.4% from a year ago — trailing twelve months through Dec 2025 was -$167.4 million (down 45.11% YoY), and the annual figure for FY2025 was -$209.5 million, down 60.57%.
  • EBT for Q4 2025 was -$41.1 million at Verastem, down from -$39.9 million in the prior quarter.
  • Over the last five years, EBT for VSTM hit a ceiling of -$15.0 million in Q1 2021 and a floor of -$43.4 million in Q1 2025.
  • Median EBT over the past 5 years was -$21.1 million (2022), compared with a mean of -$25.9 million.
  • Peak annual rise in EBT hit 60.43% in 2021, while the deepest fall reached 273.44% in 2021.
  • Verastem's EBT stood at -$16.5 million in 2021, then dropped by 1.94% to -$16.8 million in 2022, then plummeted by 80.88% to -$30.4 million in 2023, then decreased by 4.53% to -$31.8 million in 2024, then decreased by 29.4% to -$41.1 million in 2025.
  • The last three reported values for EBT were -$41.1 million (Q4 2025), -$39.9 million (Q3 2025), and -$43.0 million (Q2 2025) per Business Quant data.